Suits claiming users experienced side effects while taking Benicar, the blood pressure drug made by Daiichi Sankyo and sold by Forest Laboratories, are being consolidated before a federal judge in Camden.
The Judicial Panel on Multidistrict Litigation consolidated the suits before U.S. District Judge Robert Kugler of the District of New Jersey on April 3, and 12 of the suits from other states were transferred to New Jersey on April 7 and 8. The transfer order covers 15 suits from six states, but the JPML said it is aware of an additional 23 potential tag-along actions. The suits claim Benicar and two related drugs, Benicar HCT and Azor, may cause serious gastrointestinal problems, including sprue-like enteropathy, lymphocytic colitis, microscopic colitis and collagenous colitis, according to the JPML.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
